**4. Conclusions**

3D printing is going to change the ways of conventional drug manufacturing, and the FDM method enables the researchers to produce high quality tailored dosage forms for each patient according to their individual needs.

The results demonstrate that dissolution of tested PVA-based 3D printed placebo carriers can be characterized with the appearance of colloidal particles under 300 nm. According to the gravimetry and derived count rate data of the dynamic light scattering method, due to the erosion in the dissolution media the carrier dissolved into colloid state. The most commonly used supporting material can be upgraded into an important excipient filament used in personalized therapy. Due to the characteristics of the polymer, the phenomenon of "ghost tablets" can be abolished because the PVA-based dosage forms biodegrade in the patient's body in hours. The CAD design ensures the opportunity to add drug-releasing holes into the surface of the carrier. Utilizing this effect, extremely precise individualized treatment can be pharmaceutically engineered, and 3D printed to any patients regarding their needs. With this novel method, standardized drug release can be programmed into the CAD and gcode files of the carriers. The easy modification opportunities ensure extremely wide range of personalized medication. The following experiments would focus on the wider understanding of the behavior of the PVA and other water-soluble filaments.

**Author Contributions:** Conceptualization, B.B. (Bálint Basa) and I.A.; data curation, B.B. (Bálint Basa); formal analysis, N.K.-S. and V.F.; investigation, B.B. (Bálint Basa), G.J. and B.B. (Bence Borbás); methodology, B.B. (Bálint Basa), G.J., V.F. and E.B.; project administration, I.A.; resources, E.B.; software, B.B. (Bálint Basa); supervision, I.A.; visualization, N.K.-S.; writing—original draft, B.B. (Bálint Basa) and N.K.-S.; writing—review and editing, B.B. (Bálint Basa), N.K.-S. and I.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

#### **References**

